Stockreport

Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

Biogen Inc.  (BIIB) 
Last biogen inc. earnings: 4/22 07:12 am Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
PDF DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)Well-established sa [Read more]